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Available online 17 September 2016Skin ﬁbroblasts were obtained from a 47-year-old hereditary spastic paraplegia patient carrying a homozygous
mutation R486C in CYP7B1 (Cytochrome P450, Family 7, Subfamily B, Polypeptide 1), responsible for causing he-
reditary spastic paraplegia type 5 (SPG5). Induced pluripotent stem cells (iPSCs) were generated by transfection
with episomal plasmids carrying hOCT4, hSOX2, hKLF4, hL-MYC and hLIN28. The generated line iPS-SPG5-R486C
was transgene-free, retained the speciﬁc mutation with no additional genomic aberrations, expressed
pluripotency markers and was able to differentiate into cells of all germ layers in vitro. The generated iPS-
SPG5-R486C line may be a useful resource for disease modelling of SPG5.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Spastic paraplegia gene type 5 (SPG5) is an autosomal recessive sub-
type of hereditary spastic paraplegia caused by mutations in CYP7B1, a
gene encoding for the cytochromeP-450oxysterol 7-α-hydroxylase, es-
sential for the liver-speciﬁc alternative pathway in bile acid synthesis
(Schule et al., 2010). In this study, skin ﬁbroblasts from a 47-year-old
man were reprogrammed into iPSCs via electroporation of three epi-
somal plasmids encoding human OCT4, SOX2, KLF4, L-MYC and LIN28
(Okita et al., 2011). To determine the quality of generated iPSCs several
genotypic and functional assays were performed. The characterization
included analysis of genomic integrity given by comparative SNP analy-
sis of parental ﬁbroblasts and the respective iPSC line (Fig. 1A),
resequencing of the mutation-site (Fig. 1B) and excluding the integra-
tion of episomal plasmids by PCR (Fig. 1C). Furthermore, the expression
of stem cell marker on protein and RNA level were assessed by alkaline
phosphatase staining (ALP) (Fig. 2A), immunocytochemical stainings of(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Genomic validation of iPS-SPG5-R486C. (A) SNP array analysis of ﬁbroblast (F-SPG5-R486C) and iPSCs (iPS-SPG5-R486C) reveal genomic integrity after reprogramming. Data is
shown in whole genome view (WGV) and expressed as the weighted log2 ratio of the copy number on the left Y-axis (blue line), and the chromosome number on the X-axis. (B)
Resequencing of patient-speciﬁc mutation. Electropherograms of sequences of F-SPG5-R486C and iPS-SPG5-R486C display homozygous point mutation c.1456C N T. (C) PCR analysis
with DNA from iPS-SPG5-R486C, plasmid samples as positive control, and ddH2O as negative control with plasmid-speciﬁc primer for OCT3/4, SOX2, KLF4, and L-MYC.
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c-MYC, NANOG, DNMT3B and TDGF1 in comparison to human embry-
onic stem cell lines (HuES-H6, HuESH1 and HuES-H9) and ﬁbroblasts
(Fig. 2C). To prove the functionality of the generated iPSCs, iPSC-derived
embryoid bodies (EBs) were differentiated into cells of all three germ
layers. Generated iPSCs were able to differentiate into neurons express-
ing β-III-tubulin, muscle cells positive for α-smooth muscle actin
(SMA), and early endodermal structures like hepatic precursors detect-
able by antibodies against α-fetoprotein (AFP) (Fig. 2D).
2. Materials and methods
2.1. Reprogramming of ﬁbroblast to iPSCs
A skin biopsy was obtained from a 47-year-old man carrying a ho-
mozygous R486C mutation within CYP7B1. Loss of functions effects ofthemutation were shown by a metabolic block of the CYP7B1 substrate
27-hydroxy-cholesterol (27-OHC) in blood and cerebrospinal ﬂuid
(CSF). Serum 27-OHC was elevated by 930 ng/ml in the patient com-
pared to 89–243 ng/ml in healthy controls (Dzeletovic et al., 1995;
Norlin et al., 2000) and 131–369 ng/ml in heterozygous mutation car-
riers (Rattay et al., 2016). The biopsy was dissected and left undistribut-
ed in ﬁbroblast medium consisting of Dulbecco's modiﬁed eagle's
medium(DMEM)high glucose (Life technologies)with 10% fetal bovine
serum (FBS, Life technologies) for 10 days at 37 °C and 5% CO2 to allow
ﬁbroblasts to growout from the biopsy. Expansion of skin ﬁbroblastwas
achieved by medium change every 2–3 days. For reprogramming
1 × 105 ﬁbroblasts were electroporated (Nucleofector 2D, Lonza) with
a total of 1 μg per plasmid carrying the sequences for hOCT4, hSOX2,
hKLF4, hL-MYC and hLIN28 (Okita et al., 2011) and cultured in ﬁbroblast
medium for 1 day. After 2 days of cultivation in ﬁbroblast medium con-
taining 2 μg/l FGF-2 (Peprotech) cells were transferred to Essential 8
Fig. 2. Functional validation of iPS-SPG5-R486C. (A) Expression of alkaline phosphatase (ALP) (B) Immunocytochemical staining of OCT4 (green) and NANOG (red). Nuclei are
counterstained with DAPI (blue). Scale bar = 50 μm (C) qRT-PCR with cDNA from iPS-SPG5-R486C, HuES-H1, HuES-H6, HuES-H9 and ﬁbroblasts with the pluripotency genes OCT4,
SOX2, KLF4, C-MYC, NANOG, DNMT3B and TDGF1 normalized to the housekeeping gene GAPDH and the hESC line HuES-H6. Expression levels of pluripotency markers are comparable
to the gene expression in hESCs. (D) Immunocytochemical staining of in vitro differentiated iPSCs conﬁrmed the ability to differentiate into cells of all three germ layers, namely
ectoderm (β-III-tubulin (TUJ), scale = 100 μm), endoderm (α-fetoprotein (AFP), scale bar = 50 μm) and mesoderm (α-smooth-muscle-actin (SMA), scale bar = 50 μm). Nuclei are
counterstained with DAPI (blue).
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21–28 days, iPSC colonies were picked manually and further expanded
on Matrigel-coated 6-well dishes cultivated with E8 medium. After
reaching conﬂuency cells were split in a ratio of 1:6–1:12 with PBS/
EDTA (0.02% EDTA in PBS) and further expanded. At passage 5–10,
iPSCs were harvested for analysis or frozen in E8 medium with 40%
KOSR (Life technologies), 10% DMSO (Sigma-Aldrich) and 1 μM Y-
27632 (Abcam Biochemicals).2.2. SNP array analysis
DNA was isolated using the DNeasy blood & tissue kit (Qiagen) ac-
cording to manufacturer's guidelines. The SNP array was performed
using the Affymetrix CytoScan HD technology (Affymetrix). For analy-
sis, 2 μg of DNA of the original ﬁbroblast line with the respective iPSCline were included. Raw data was analyzed using Affymetrix
Chromsome Analysis Suite (ChAS) 2.0 software.
2.3. Sequencing of mutation site
Sanger sequencing of the mutation (c.1456C N T) of CYP7B1 gene
was carried out on 3130xl Genetic Analyzer (Applied Biosystems)
using a primer set that ﬂank the mutation site according to standard
procedures and analyzed with the Staden 2.0.0b10 software (Staden
Sourceforge).
2.4. Non-integration of transgenes
DNA was isolated using the DNeasy blood & tissue kit (Qiagen) ac-
cording to manufacturer's guidelines. The three episomal plasmids
(pCXLE-hUL, pCXLE-hSK and pCXLE-hOCT4) were used as positive
Table 3
Antibodies used for validation of pluripotency genes and in vitro differentiation potential.
Antibody Dilution Manufacturer
Pluripotency rabbit anti-NANOG 1:50 Stemgent
goat anti-OCT4 1:100 Santa-Cruz
In vitro differentiation mouse anti-AFP 1:200 Sigma-Aldrich
mouse anti-SMA 1:100 Dako
Mouse anti-TUJ 1:1000 Sigma-Aldrich
Table 1
Primers (Okita et al., 2011) used for integration analysis by PCR.
Forward sequence Reverse sequence
KLF4 CCACCTCGCCTTACACATGAAG TAGCGTAAAAGGAGCAACATAG
L-MYC GGCTGAGAAGAGGATGGCTAC TTTGTTTGACAGGAGCGACAAT
OCT-3/4 CATTCAAACTGAGGTAAGGG TAGCGTAAAAGGAGCAACATAG
SOX-2 TTCACATGTCCCAGCACTACCAG TTTGTTTGACAGGAGCGACAAT
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(Promega) according to manufacturer's instruction. PCR products
were studied by gel electrophoresis on a 2% agarose gel with Midori
Green.GeneRuler DNA Ladderwasused as size ladder. The plasmid spe-
ciﬁc primers are listed in Table 1.
2.5. Alkaline phosphatase staining
iPSCs were cultivated on 12-well plates until conﬂuency of 60–80%.
Cells were ﬁxed in 4% paraformaldehyde (PFA) for 1 min and washed 3
timeswith PBS. Staining solution consist of 40 μl Naphthol AS-MX phos-
phate alkaline solution (Sigma-Aldrich) and 1 ml Fast Red (1 mg/ml,
Sigma Aldrich). After 30 min ALP-positive colonies were stained dark
red and solution was replaced by PBS.
2.6. Immunocytochemical staining
iPSCs were cultivated on 24-well plates on coverslips until
conﬂuency of 60–80%. Cells were ﬁxed in 4% paraformaldehyde (PFA)
for 15min andwashed 3 timeswith PBS. Permeabilization and blocking
was achieved by incubation in blocking buffer (PBS, 1% FCS, 0.1% Triton
X-100) for 45min. Primary antibody (see Table 3)was applied for 1 h at
room temperature (RT) followed by 3 times washing in PBS and subse-
quent incubation of secondary antibody (Alexa488 or Alexa568 diluted
1:300 (Life technologies)) in the dark at RT for 1 h. After 3washing steps
in PBS, DAPI (1:10,000)was used for nuclear counterstaining by incuba-
tion for 15 min at RT in the dark. Cells were embedded in ProLong Dia-
mond Antifade Mountant. Images were captured with Axio Imager Z1
with ApoTome (Zeiss).
2.7. qRT-PCR of pluripotency marker
Total RNAwas isolated from iPSCs using theHigh Pure RNA Isolation
Kit (Roche) followed by reverse transcription into cDNA using the
Transcriptor High Fidelity cDNA Synthesis Kit (Roche) according to
manufacturer's guidelines. qPCR reactions were run with Light Cycler
480 SYBR Green I Master (Roche) and primers speciﬁc for pluripotency
genes (see Table 2). CT-values were normalized using 2-ΔΔCt with
human embryonic stem cells (hESCs HuES-H6) as reference and
GAPDH as housekeeping gene.
2.8. In vitro differentiation potential
iPSCs were detached and resuspended in EB medium consisting of
80% DMEM/F12 (Life technologies), 20% KOSR, 1× NEAA, 1× Pen/Table 2
Primers used for validation of pluripotency genes.
Forward sequence Reverse sequence
c-MYC ATTCTCTGCTCTCCTCGACG CTGTGAGGAGGTTTGCTGTG
DNMT3 ACGACACAGAGGACACACAT AAGCCCTTGATCTTTCCCCA
GAPDH AGGTCGGAGTCAACGGATTT ATCTCGCTCCTGGAAGATGG
KLF4 CCATCTTTCTCCACGTTCGC CGTTGAACTCCTCGGTCTCT
NANOG CAAAGGCAAACAACCCACTT TGCGTCACACCATTGCTATT
OCT-4 GGAAGGTATTCAGCCAAACG CTCCAGGTTGCCTCTCACTC
SOX-2 TGATGGAGACGGAGCTGAAG GCTTGCTGATCTCCGAGTTG
TDGF1 GGTCTGTGCCCCATGACA AGTTCTGGAGTCCTGGAAGCStrep, 2mM L-Glutamine and 0.1mM2-Mercaptoethanol on AggreWell
800 plates (Stemcell Technologies) with medium change at day 2. On
day 4, EBs were collected and plated on coverslips coatedwith 0.1% gel-
atine (Sigma-Aldrich). EB medium was exchanged every other day and
cellswere cultivated for additional 2–3weeks. EBswereﬁxed for 15min
in 4% PFA for immunocytochemical analysis using AFP (α-fetoprotein),
SMA (α-smooth muscle actin) and TUJ (β-III-tubulin) as antibodies for
the three germ layers (see Table 3).
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